Skip to main content
Erschienen in: Supportive Care in Cancer 2/2020

08.05.2019 | Original Article

Exploring the impact of providing men with information about potential prostate cancer treatment options prior to receiving biopsy results

verfasst von: Brindha Pillay, Daniel Moon, Denny Meyer, Helen Crowe, Sarah Mann, Nicholas Howard, Addie Wootten, Mark Frydenberg

Erschienen in: Supportive Care in Cancer | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

There is little research assessing the impact of providing men with information about prostate cancer (PCa) treatment options at the time of referral for a prostate biopsy. Study objectives were to determine whether receiving an information booklet about PCa treatment options prior to receiving biopsy results was acceptable to patients, and if receiving this information influenced levels of anxiety, depression, distress, and treatment decisional conflict.

Methods

Between June 2016 and September 2017, a randomised block design was used to allocate patients from an Australian urology practice into the intervention or control group. Patients in the intervention group were provided with written information about treatment options for localised PCa prior to their biopsy. Outcome measures including the Distress Thermometer, Generalised Anxiety Disorder-7, Patient Health Questionnaire-9, and Decisional Conflict Scale were completed pre-biopsy and 2–3 weeks post-biopsy. Ninety-eight patients referred for an initial prostate biopsy for an elevated PSA test or suspicious digital rectal exam participated in the study (response rate = 78%).

Results

Multimodal repeated-measures analyses showed no significant differences between control and intervention groups in changes in distress, anxiety, or depression from pre- to post-biopsy, and in decisional conflict post-diagnosis (all p > .05). Thirty-five (87%) patients believed that the resource made it easier to understand subsequent explanation of treatment options, and 51 patients (98%) who received the intervention preferred to be given information at that time.

Conclusions

Providing patients with information about treatment options prior to biopsy did not impact on changes in psychological distress and decisional conflict post-biopsy. However, the majority of patients preferred to be given such information at this time point.
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin D, Forman D, Bray F (2012) GLOBOCAN 2012 v1.0 cancer incidence and mortality worldwide. IARC CancerBase No. 11. International Agency for Research on Cancer, Lyon Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin D, Forman D, Bray F (2012) GLOBOCAN 2012 v1.0 cancer incidence and mortality worldwide. IARC CancerBase No. 11. International Agency for Research on Cancer, Lyon
3.
Zurück zum Zitat Hellenthal N, Ellison L (2008) How patients make treatment choices? Nat Clin Pract Urol 5(8):426–433CrossRefPubMed Hellenthal N, Ellison L (2008) How patients make treatment choices? Nat Clin Pract Urol 5(8):426–433CrossRefPubMed
5.
Zurück zum Zitat Zeliadt SB, Ramsey SD, Penson DF, Hall IJ, Ekwueme DU, Stroud L, Lee JW (2006) Why do men choose one treatment over another? A review of patient decision making for localised prostate cancer. Cancer 106(9):1865–1874CrossRefPubMed Zeliadt SB, Ramsey SD, Penson DF, Hall IJ, Ekwueme DU, Stroud L, Lee JW (2006) Why do men choose one treatment over another? A review of patient decision making for localised prostate cancer. Cancer 106(9):1865–1874CrossRefPubMed
8.
Zurück zum Zitat Chabrera CM, Zabalegui A, Bonet M, Caro M, Areal J, Gonzalez JR, Font A (2015) A decision aid to support informed choices for patients recently diagnosed with prostate cancer: a randomized controlled trial. Cancer Nurs 38(3):E42–E50CrossRefPubMed Chabrera CM, Zabalegui A, Bonet M, Caro M, Areal J, Gonzalez JR, Font A (2015) A decision aid to support informed choices for patients recently diagnosed with prostate cancer: a randomized controlled trial. Cancer Nurs 38(3):E42–E50CrossRefPubMed
9.
Zurück zum Zitat Isebaert S, Van Audenhove C, Haustermans K, Junius S, Joniau S, De Ridder K, Van Poppel H (2008) Evaluating a decision aid for patients with localized prostate cancer in clinical practice. Urol Int 81(4):383–388CrossRefPubMed Isebaert S, Van Audenhove C, Haustermans K, Junius S, Joniau S, De Ridder K, Van Poppel H (2008) Evaluating a decision aid for patients with localized prostate cancer in clinical practice. Urol Int 81(4):383–388CrossRefPubMed
10.
Zurück zum Zitat Violette PD, Agoritsas T, Alexander P, Riikonen J, Santti H, Agarwal A, Bhatnagar N, Dahm P, Montori V, Guyatt GH, Tikkinen KAO (2015) Decision aids for localized prostate cancer treatment choice: systematic review and meta-analysis. CA Cancer J Clin 65(3):239CrossRefPubMed Violette PD, Agoritsas T, Alexander P, Riikonen J, Santti H, Agarwal A, Bhatnagar N, Dahm P, Montori V, Guyatt GH, Tikkinen KAO (2015) Decision aids for localized prostate cancer treatment choice: systematic review and meta-analysis. CA Cancer J Clin 65(3):239CrossRefPubMed
12.
Zurück zum Zitat Zeliadt SB, Moinpour CM, Blough DK, Penson DF, Hall IJ, Smith JL, Ekwueme DU, Thompson IM, Keane TE, Ramsey SD (2010) Preliminary treatment considerations among men with newly diagnosed prostate cancer. Am J Manag Care 16(5):e121–e130PubMed Zeliadt SB, Moinpour CM, Blough DK, Penson DF, Hall IJ, Smith JL, Ekwueme DU, Thompson IM, Keane TE, Ramsey SD (2010) Preliminary treatment considerations among men with newly diagnosed prostate cancer. Am J Manag Care 16(5):e121–e130PubMed
13.
Zurück zum Zitat Zeliadt SB, Hannon PA, Trivedi RB, Bonner LB, Vu TT, Simons C, Kimmie CA, Hu EY, Zipperer C, Lin DW (2013) A preliminary exploration of the feasibility of offering men information about potential prostate cancer treatment options before they know their biopsy results. BMC Med Inform Decis Mak 13(19). https://doi.org/10.1186/1472-6947-13-19 Zeliadt SB, Hannon PA, Trivedi RB, Bonner LB, Vu TT, Simons C, Kimmie CA, Hu EY, Zipperer C, Lin DW (2013) A preliminary exploration of the feasibility of offering men information about potential prostate cancer treatment options before they know their biopsy results. BMC Med Inform Decis Mak 13(19). https://​doi.​org/​10.​1186/​1472-6947-13-19
14.
Zurück zum Zitat Chambers SK, Zajdlewicz L, Youlden DR, Holland JC, Dunn J (2014) The validity of the distress thermometer in prostate cancer populations. Psychooncology 23:195–203CrossRefPubMed Chambers SK, Zajdlewicz L, Youlden DR, Holland JC, Dunn J (2014) The validity of the distress thermometer in prostate cancer populations. Psychooncology 23:195–203CrossRefPubMed
19.
Zurück zum Zitat O'Connor AM (1995) Validation of a decisional conflict scale. Med Decis Mak 15(1):25–30CrossRef O'Connor AM (1995) Validation of a decisional conflict scale. Med Decis Mak 15(1):25–30CrossRef
20.
Zurück zum Zitat Ernstmann N, Weissbach L, Herden J, Winter N, Ansmann L (2017) Patient–physician communication and health-related quality of life of patients with localised prostate cancer undergoing radical prostatectomy – a longitudinal multilevel analysis. BJU Int 119(3):396–405. https://doi.org/10.1111/bju.13495 CrossRefPubMed Ernstmann N, Weissbach L, Herden J, Winter N, Ansmann L (2017) Patient–physician communication and health-related quality of life of patients with localised prostate cancer undergoing radical prostatectomy – a longitudinal multilevel analysis. BJU Int 119(3):396–405. https://​doi.​org/​10.​1111/​bju.​13495 CrossRefPubMed
Metadaten
Titel
Exploring the impact of providing men with information about potential prostate cancer treatment options prior to receiving biopsy results
verfasst von
Brindha Pillay
Daniel Moon
Denny Meyer
Helen Crowe
Sarah Mann
Nicholas Howard
Addie Wootten
Mark Frydenberg
Publikationsdatum
08.05.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 2/2020
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-019-04847-5

Weitere Artikel der Ausgabe 2/2020

Supportive Care in Cancer 2/2020 Zur Ausgabe

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.